Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-955176 and Dolutegravir Interaction Study
NCT02715479Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BMS-955176 in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by ViiV Healthcare. Primary endpoints: Maximum observed plasma concentration for DTG, Area under the concentration-time curve in 1 dosing interval for DTG and 2 more. Started Apr 2016; status: completed.
02
Drugs
BMS-955176
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02715479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02715479.